Rapport Therapeutics Hits New 52-Week High of $43.65

Rapport Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 43.65 on June 30, 2026. This achievement marks a notable increase from its 52-week low of USD 11.05, reflecting a substantial upward trend in the stock's performance over the past year. In the context of broader market performance, Rapport Therapeutics has outpaced the S&P 500, with a one-year performance rate of 20.86%. The company, which currently holds a market capitalization of USD 1,331 million, continues to navigate the competitive landscape of the biotechnology industry. Despite its loss-making status, indicated by a P/E ratio that remains unavailable, Rapport Therapeutics maintains a price-to-book ratio of 2.75. The company's financial metrics, including a debt-equity ratio of -1.01 and an exceptionally high negative return on equity, highlight the complexities of its financial health. As the stock continues to gain traction, it remains a focal point within its industry.